Novantrone (mitoxandrone)

Approved by the FDA in 2000, Novantrone® (generic name: mitoxantrone) is prescribed to treat various types of cancer, leukemia, and to reduce neurological disability and the frequency of relapses in patients with multiple sclerosis (secondary progressive, progressive relapsing and worsening relapsing-remitting). Novantone is not indicated in the treatment of patients with primary progressive multiple sclerosis.

In 2005, the FDA issued a warning notifying healthcare professionals of the risk of severe heart problems connected with the use of mitoxantrone. Mitoxantrone has been connected to fatal heart problems (including heart failure) and dangerous blood disorders which result in a bone marrow suppression and a restraint of the body's ability to fight infections. In effect, mitoxantrone is given to intentionally suppress the immune system to lessen its attack on the body. While this is usually an effective means of fighting certain diseases, it also poses great health risks.

More common side effects are:

• A blue-green color of urine for 24 hours after receiving Novantrone.
• Mild or moderate nausea.
• Menstrual irregularities in women.
• Hair loss that may be mild to moderate (hair will usually grow back after treatment is discontinued).

Possible, more sever side effects are:

• Fever
• Chills
• Sore throat or cough
• Sores on lips or in mouth
• Shortness of breath
• Stomach pain
• Vomiting
• Diarrhea
• Painful or difficult urination
• Uneven or rapid heartbeat
• Swollen feet or ankles
• Unusual bleeding or bruising
• Pain, swelling, redness or irritation at the injection site

If you believe your Novantrone use has put you or a loved one in danger, please fill out our Case Review Contact Form to the right on this page to find out what your case is worth.